Influence of an n-3 long-chain polyunsaturated fatty acid-enriched diet on experimentally induced synovitis in horses.
Authors: Ross-Jones T N, McIlwraith C W, Kisiday J D, Hess T M, Hansen D K, Black J
Journal: Journal of animal physiology and animal nutrition
Summary
# Editorial Summary: N-3 Fatty Acids and Joint Inflammation in Horses Omega-3 long-chain polyunsaturated fatty acids (EPA and DHA) have demonstrated anti-inflammatory properties across several species, yet their effects within equine joint disease remain poorly characterised. Ross-Jones and colleagues investigated whether a 91-day supplementation protocol delivering 40 g/day of n-3 LCPUFA would attenuate the inflammatory cascade in experimentally induced synovitis, using 12 mature mares randomised to either control or treatment diets, with joint inflammation subsequently triggered via intra-articular IL-1β injection. Supplemented horses showed marked enrichment of EPA and DHA in both serum phospholipids and synovial fluid; however, the treatment diet produced no significant reduction in synovial fluid prostaglandin E2 or matrix metalloproteinase activity—traditionally considered key inflammatory mediators in degenerative joint disease. The most notable finding was a reduction in ADAMTS-4 messenger RNA expression within synovial tissue of supplemented horses, suggesting potential chondroprotective activity at the tissue level despite absent systemic biomarker changes. For practitioners, whilst these results temper expectations about dramatic improvements in joint inflammation markers, the localised suppression of aggrecanase expression warrants continued investigation of n-3 supplementation as a complementary strategy in joint disease management, particularly given the safety profile and growing evidence for broader musculoskeletal benefits of omega-3 supplementation in equine athletes.
Read the full abstract on PubMed
Practical Takeaways
- •N-3 LCPUFA supplementation successfully accumulates EPA and DHA in joint tissues, supporting tissue penetration of these compounds
- •While synovial fluid inflammatory markers (PGE2, MMP) were not reduced by supplementation, the lower ADAMTS-4 expression suggests potential protective effects on cartilage matrix degradation that warrant further investigation
- •Current evidence is insufficient to recommend n-3 LCPUFA as a primary joint therapy, but tissue-level gene expression changes suggest continued investigation may be warranted
Key Findings
- •90-day n-3 LCPUFA supplementation (40 g/day) significantly increased serum phospholipid and synovial fluid EPA and DHA concentrations compared to control horses
- •Recombinant equine IL-1β injection successfully induced inflammatory response in all horses, but dietary treatment did not affect synovial fluid PGE2 content or MMP activity
- •N3FA-supplemented horses showed significantly lower ADAMTS-4 mRNA expression in synovial tissue compared to controls at 8 hours post-injection
- •Despite bioaccumulation of EPA and DHA in synovial fluid, dietary n-3 LCPUFA did not modify most measured inflammatory biomarkers in synovial fluid